查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1947883

摄护腺健康市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、设备、最终用户、功能、安装类型、设备划分

Prostate Health Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Device, End User, Functionality, Installation Type, Equipment
出版日期: | 出版商: Global Insight Services | 英文 322 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计摄护腺健康市场规模将从2024年的355亿美元成长到2034年的618亿美元，复合年增长率约为5.1%。前列腺健康市场涵盖旨在诊断、治疗和管理前列腺相关疾病（包括良性前列腺增生和前列腺癌）的产品和服务，包括药物、微创手术和诊断工具。前列腺疾病盛行率的不断上升和公众意识的提高正在推动治疗方法的创新。对早期检测和个人化医疗的重视正在塑造市场动态，并推动影像诊断技术和生物标记研究的发展。

前列腺健康市场正经历强劲成长，这主要得益于公众意识的提高和治疗方法的进步。製药业是推动市场成长的主要力量，荷尔蒙疗法和化疗药物已成为前列腺疾病治疗的关键手段。生物製药和免疫疗法药物的重要性日益凸显，反映了精准医疗的发展趋势。诊断产业紧随其后，磁振造影（MRI）和超音波等影像技术在前列腺健康的早期检测和后续观察中发挥关键作用。基因检测和生物标记分析正逐渐成为风险评估和治疗方案製定的有效工具。外科手术领域，尤其是微创手术（如机器人辅助手术），因其更高的精准度和更短的恢復时间而备受关注。积极的后续观察和生活方式管理也正成为综合前列腺健康策略的重要组成部分。远端医疗和数位健康平台的创新正在促进远端监测和病人参与，进一步推动市场成长。对预防保健和早期疗育的重视将继续塑造市场动态。

市场区隔
类型 良性摄护腺增生、摄护腺癌、摄护腺炎
产品 药品、手术器材、诊断测试、营养补充品、摄护腺保健食品
服务 筛检服务、咨询服务、治疗服务、监测服务、復健服务
科技 核磁振造影、超音波、切片检查设备、PSA检测、基因组检测
适用的 医院、诊所、门诊手术中心、居家医疗、研究机构
医疗设备 雷射设备、冷冻治疗设备、射频消融术设备
最终用户 医疗保健提供者、患者和研究机构
功能 诊断、治疗与预防
安装类型 携带式和固定式
装置 诊断影像设备、手术设备、监护设备

前列腺健康市场正经历市场份额的动态变化，现有企业保持着主导地位，而新参与企业则不断推出创新解决方案。先进治疗方法和诊断工具的引入导致定价策略竞争日益激烈。近期推出的产品，主要集中在微创手术和个人化医疗方面，体现了以患者为中心的医疗服务趋势。这种发展加剧了市场竞争，并促使各公司加强研发投入，以增​​强其产品阵容。摄护腺健康市场的竞争异常激烈，主要企业互相参照，力求竞争优势。监管因素，尤其是在北美和欧洲，对市场动态的塑造至关重要，严格的指导方针影响产品核可和市场准入。各公司正透过加大合规和品质保证方面的投入来应对这些监管要求。由于技术进步、前列腺疾病盛行率的上升以及对早期检测和治疗日益重视，该市场有望实现成长。

主要趋势和驱动因素：

由于公众意识的提高和医疗技术的进步，前列腺健康市场正经历强劲增长。主要趋势包括微创治疗方法的广泛应用以及针对前列腺疾病的新型治疗方法的研发。这些创新对医疗服务提供者极具吸引力，因为它们能够改善患者预后并缩短復原时间。此外，全球人口老化也是一个重要的驱动因素。由于摄护腺健康问题在老年男性中更为普遍，这种人口结构变化正在推动对有效诊断和治疗方案的需求。新兴市场医疗保健支出的成长和医疗服务可近性的提高进一步促进了市场扩张。此外，研发投入的增加正在推动人们对摄护腺健康的认识取得突破性进展，从而为更具针对性和个人化的治疗方案铺平道路。专注于创新解决方案和策略合作的公司能够更好地掌握这些机会，确保摄护腺健康市场的持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 良性摄护腺增生
    • 摄护腺癌
    • 摄护腺炎
  • 市场规模及预测：依产品划分
    • 药物
    • 外科器械
    • 诊断测试
    • 补充
    • 前列腺保健食品
  • 市场规模及预测：依服务划分
    • 筛检服务
    • 咨询服务
    • 治疗服务
    • 监控服务
    • 復健服务
  • 市场规模及预测：依技术划分
    • MRI
    • 超音波
    • 切片检查装置
    • PSA检测
    • 基因组检测
  • 市场规模及预测：依应用领域划分
    • 医院
    • 临床科
    • 门诊手术中心
    • 居家医疗
    • 研究所
  • 市场规模及预测：依设备划分
    • 雷射设备
    • 冷冻疗法设备
    • 射频消融装置
  • 市场规模及预测：依最终用户划分
    • 医疗保健提供者
    • 病人
    • 研究机构
  • 市场规模及预测：依功能划分
    • 诊断
    • 透过治疗方法
    • 预防
  • 市场规模及预测：依安装类型划分
    • 可携式的
    • 固定的
  • 市场规模及预测：依设备划分
    • 诊断影像设备
    • 手术器械
    • 监测设备

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Astellas Pharma
  • Ferring Pharmaceuticals
  • Myriad Genetics
  • Tolmar Pharmaceuticals
  • Veru
  • Sophiris Bio
  • Nymox Pharmaceutical
  • Spectrum Pharmaceuticals
  • Advanced Accelerator Applications
  • Bavarian Nordic
  • Progenics Pharmaceuticals
  • Onco Genex Pharmaceuticals
  • Nant Kwest
  • Amgen Biosimilars
  • Dendreon Pharmaceuticals
  • Endo Pharmaceuticals
  • Astra Zeneca Biosimilars
  • Bristol Myers Squibb Biosimilars
  • Novartis Biosimilars
  • Sanofi Biosimilars

第九章：关于我们

简介目录
Product Code: GIS21014

Prostate Health Market is anticipated to expand from $35.5 billion in 2024 to $61.8 billion by 2034, growing at a CAGR of approximately 5.1%. The Prostate Health Market encompasses products and services aimed at diagnosing, treating, and managing prostate-related conditions, including benign prostatic hyperplasia and prostate cancer. This market includes pharmaceuticals, minimally invasive procedures, and diagnostic tools. Rising prevalence of prostate disorders and increasing awareness drive innovation in treatment options. Emphasis on early detection and personalized medicine shapes market dynamics, fostering advancements in imaging technologies and biomarker research.

The Prostate Health Market is experiencing robust growth, propelled by increasing awareness and advancements in treatment modalities. The pharmaceutical segment leads performance, with hormone therapy and chemotherapy drugs being pivotal in addressing prostate conditions. Biologics and immunotherapy drugs are gaining prominence, reflecting a shift towards personalized medicine. The diagnostic segment follows, with imaging techniques such as MRI and ultrasound playing a crucial role in early detection and monitoring of prostate health. Genetic testing and biomarker analysis are emerging as valuable tools for risk assessment and treatment planning. The surgical segment, particularly minimally invasive procedures like robotic-assisted surgery, is gaining traction due to enhanced precision and reduced recovery times. Active surveillance and lifestyle management are also becoming integral to comprehensive prostate health strategies. Innovations in telemedicine and digital health platforms are facilitating remote monitoring and patient engagement, further driving market growth. The focus on preventative care and early intervention continues to shape the market dynamics.

Market Segmentation
TypeBenign Prostatic Hyperplasia, Prostate Cancer, Prostatitis
ProductMedications, Surgical Devices, Diagnostic Tests, Supplements, Prostate Health Foods
ServicesScreening Services, Consultation Services, Treatment Services, Monitoring Services, Rehabilitation Services
TechnologyMRI, Ultrasound, Biopsy Devices, PSA Testing, Genomic Testing
ApplicationHospitals, Clinics, Ambulatory Surgical Centers, Home Care, Research Institutes
DeviceLaser Devices, Cryotherapy Devices, Radiofrequency Ablation Devices
End UserHealthcare Providers, Patients, Research Organizations
FunctionalityDiagnostic, Therapeutic, Preventive
Installation TypePortable, Fixed
EquipmentImaging Equipment, Surgical Equipment, Monitoring Equipment

The Prostate Health Market is experiencing a dynamic shift in market share, with established players maintaining dominance while new entrants introduce innovative solutions. Pricing strategies are competitive, driven by the introduction of advanced therapies and diagnostic tools. Recent product launches focus on minimally invasive procedures and personalized medicine, reflecting a trend towards patient-centric care. This evolution is fostering a competitive landscape, encouraging companies to invest in research and development to enhance their product offerings. Competition in the Prostate Health Market is intense, with key players benchmarking against each other to gain a competitive edge. Regulatory influences, particularly in North America and Europe, are critical in shaping market dynamics, with stringent guidelines affecting product approvals and market entry. Companies are navigating these regulations by investing in compliance and quality assurance. The market is poised for growth, driven by technological advancements, increasing prevalence of prostate disorders, and a growing emphasis on early detection and treatment.

Geographical Overview:

The prostate health market is witnessing diverse growth across global regions, each presenting unique opportunities. North America leads with advanced healthcare infrastructure and high awareness about prostate health. Increased government initiatives and research funding further drive the market. Europe follows, with a strong focus on early diagnosis and innovative treatment options. The region's robust healthcare policies enhance market expansion. Asia Pacific emerges as a lucrative growth pocket, propelled by rising healthcare expenditures and growing awareness about men's health. Countries like China and India are at the forefront, investing in healthcare advancements and expanding access to medical services. Latin America shows potential, with Brazil and Mexico enhancing healthcare systems and increasing prostate health awareness. The Middle East & Africa are gradually recognizing the importance of prostate health, with countries like the UAE investing in healthcare infrastructure and public health campaigns to address this crucial issue.

The imposition of global tariffs, coupled with geopolitical uncertainties, is significantly influencing the Prostate Health Market, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are navigating these challenges by investing in local research and development to mitigate dependency on imported medical technologies. China is accelerating its focus on domestic innovation in response to trade restrictions, aiming to bolster its healthcare industry. Taiwan, while a key player in medical device manufacturing, must carefully balance its economic ties amidst US-China tensions. The global prostate health market is experiencing steady growth, driven by rising awareness and technological advancements, with expectations of significant expansion by 2035. Middle East conflicts continue to pose risks to global supply chains and energy prices, potentially affecting production costs and timelines.

Key Trends and Drivers:

The prostate health market is experiencing robust growth, driven by increasing awareness and advancements in medical technologies. Key trends include the rise of minimally invasive treatments and the development of novel therapeutics targeting prostate conditions. These innovations are improving patient outcomes and reducing recovery times, making them highly attractive to healthcare providers. Additionally, the aging global population is a significant driver, as prostate health issues are more prevalent among older men. This demographic shift is fueling demand for effective diagnostic and treatment solutions. Increased healthcare spending and improved access to medical services in emerging markets are further contributing to market expansion. Moreover, growing investment in research and development is leading to breakthroughs in understanding prostate health, paving the way for more targeted and personalized treatment options. Companies focusing on innovative solutions and strategic partnerships are well-positioned to capitalize on these opportunities, ensuring sustained growth in the prostate health market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Installation Type
  • 2.10 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Benign Prostatic Hyperplasia
    • 4.1.2 Prostate Cancer
    • 4.1.3 Prostatitis
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Medications
    • 4.2.2 Surgical Devices
    • 4.2.3 Diagnostic Tests
    • 4.2.4 Supplements
    • 4.2.5 Prostate Health Foods
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Screening Services
    • 4.3.2 Consultation Services
    • 4.3.3 Treatment Services
    • 4.3.4 Monitoring Services
    • 4.3.5 Rehabilitation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 MRI
    • 4.4.2 Ultrasound
    • 4.4.3 Biopsy Devices
    • 4.4.4 PSA Testing
    • 4.4.5 Genomic Testing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Ambulatory Surgical Centers
    • 4.5.4 Home Care
    • 4.5.5 Research Institutes
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Laser Devices
    • 4.6.2 Cryotherapy Devices
    • 4.6.3 Radiofrequency Ablation Devices
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Healthcare Providers
    • 4.7.2 Patients
    • 4.7.3 Research Organizations
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Diagnostic
    • 4.8.2 Therapeutic
    • 4.8.3 Preventive
  • 4.9 Market Size & Forecast by Installation Type (2020-2035)
    • 4.9.1 Portable
    • 4.9.2 Fixed
  • 4.10 Market Size & Forecast by Equipment (2020-2035)
    • 4.10.1 Imaging Equipment
    • 4.10.2 Surgical Equipment
    • 4.10.3 Monitoring Equipment

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Device
      • 5.2.1.7 End User
      • 5.2.1.8 Functionality
      • 5.2.1.9 Installation Type
      • 5.2.1.10 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Device
      • 5.2.2.7 End User
      • 5.2.2.8 Functionality
      • 5.2.2.9 Installation Type
      • 5.2.2.10 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Device
      • 5.2.3.7 End User
      • 5.2.3.8 Functionality
      • 5.2.3.9 Installation Type
      • 5.2.3.10 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Device
      • 5.3.1.7 End User
      • 5.3.1.8 Functionality
      • 5.3.1.9 Installation Type
      • 5.3.1.10 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Device
      • 5.3.2.7 End User
      • 5.3.2.8 Functionality
      • 5.3.2.9 Installation Type
      • 5.3.2.10 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Device
      • 5.3.3.7 End User
      • 5.3.3.8 Functionality
      • 5.3.3.9 Installation Type
      • 5.3.3.10 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Device
      • 5.4.1.7 End User
      • 5.4.1.8 Functionality
      • 5.4.1.9 Installation Type
      • 5.4.1.10 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Device
      • 5.4.2.7 End User
      • 5.4.2.8 Functionality
      • 5.4.2.9 Installation Type
      • 5.4.2.10 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Device
      • 5.4.3.7 End User
      • 5.4.3.8 Functionality
      • 5.4.3.9 Installation Type
      • 5.4.3.10 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Device
      • 5.4.4.7 End User
      • 5.4.4.8 Functionality
      • 5.4.4.9 Installation Type
      • 5.4.4.10 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Device
      • 5.4.5.7 End User
      • 5.4.5.8 Functionality
      • 5.4.5.9 Installation Type
      • 5.4.5.10 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Device
      • 5.4.6.7 End User
      • 5.4.6.8 Functionality
      • 5.4.6.9 Installation Type
      • 5.4.6.10 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Device
      • 5.4.7.7 End User
      • 5.4.7.8 Functionality
      • 5.4.7.9 Installation Type
      • 5.4.7.10 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Device
      • 5.5.1.7 End User
      • 5.5.1.8 Functionality
      • 5.5.1.9 Installation Type
      • 5.5.1.10 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Device
      • 5.5.2.7 End User
      • 5.5.2.8 Functionality
      • 5.5.2.9 Installation Type
      • 5.5.2.10 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Device
      • 5.5.3.7 End User
      • 5.5.3.8 Functionality
      • 5.5.3.9 Installation Type
      • 5.5.3.10 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Device
      • 5.5.4.7 End User
      • 5.5.4.8 Functionality
      • 5.5.4.9 Installation Type
      • 5.5.4.10 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Device
      • 5.5.5.7 End User
      • 5.5.5.8 Functionality
      • 5.5.5.9 Installation Type
      • 5.5.5.10 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Device
      • 5.5.6.7 End User
      • 5.5.6.8 Functionality
      • 5.5.6.9 Installation Type
      • 5.5.6.10 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Device
      • 5.6.1.7 End User
      • 5.6.1.8 Functionality
      • 5.6.1.9 Installation Type
      • 5.6.1.10 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Device
      • 5.6.2.7 End User
      • 5.6.2.8 Functionality
      • 5.6.2.9 Installation Type
      • 5.6.2.10 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Device
      • 5.6.3.7 End User
      • 5.6.3.8 Functionality
      • 5.6.3.9 Installation Type
      • 5.6.3.10 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Device
      • 5.6.4.7 End User
      • 5.6.4.8 Functionality
      • 5.6.4.9 Installation Type
      • 5.6.4.10 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Device
      • 5.6.5.7 End User
      • 5.6.5.8 Functionality
      • 5.6.5.9 Installation Type
      • 5.6.5.10 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Astellas Pharma
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Ferring Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Myriad Genetics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Tolmar Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Veru
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sophiris Bio
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Nymox Pharmaceutical
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Spectrum Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Advanced Accelerator Applications
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Bavarian Nordic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Progenics Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Onco Genex Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Nant Kwest
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Amgen Biosimilars
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Dendreon Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Endo Pharmaceuticals
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Astra Zeneca Biosimilars
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Bristol Myers Squibb Biosimilars
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Novartis Biosimilars
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Sanofi Biosimilars
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us